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Abstract Cells transformed by human adenovirus 12 (Adl2) 
exhibit extremely low surface levels of MHC class I molecules 
and contain reduced levels of class I heavy chain mRNAs. We 
report that levels of MHC-encoded TAP1 and LMP2 mRNAs 
are also down-regulated in Ad 12-transformed rat cells, and that 
transcription of rat TAP1 and LMP2 transcripts is directed from 
a 564 bp intergenic region which is significantly less active in 
Adl2-transformed cells compared to those transformed with 
Ad5. Our results suggest that, in common with MHC class I gene 
expression, TAP1 and LMP2 gene expression is reduced mainly 
at the level of transcription in Ad 12-transformed cells. 
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1. Introduction 
Major histocompatibility complex (MHC) class I molecules 
are cell surface glycoproteins which play a key role in immune 
recognition of virally infected and transformed cells [1]. Class 
I molecules are heterodimers consisting of a polymorphic 
heavy chain non-covalently linked to an invariant light chain, 
32-microglobulin. They function by presenting intracellularly 
processed peptides on the cell surface. Class I molecules 
loaded with foreign peptide are recognised by cytotoxic T cells 
which can then lyse the presenting cell [2]. A number of hu-
man cancers have been identified with reduced levels of sur-
face class I molecules and it has been postulated that this may 
represent a mechanism whereby tumour cells can escape im-
mune surveillance [3]. 
Transport of class I molecules to the cell surface is depend-
ent on their binding to peptide in the endoplasmic reticulum 
[4,5]. It has been shown that these peptides, which arise from 
cleavage of proteins in the cytosol, are actively carried into the 
endoplasmic reticulum by a specific protein complex termed 
the transporter associated with antigen processing or TAP [6]. 
TAP consists of two subunits, TAP1 and TAP2, which are 
encoded by separate genes. Cells deleted for TAP1 and TAP2 
have very low levels of surface class I molecules demonstrat-
ing that TAP expression is essential for antigen presentation 
[7,8]. The genes encoding TAP1 and TAP2 are located within 
the class II region of the MHC and are very closely linked to 
two other genes called LMP2 and LMP7 [9]. These genes 
encode γ-interferon inducible components of the proteasome, 
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a large complex with protease activity thought to be involved 
in the production of antigenic peptides [10]. Cells deleted for 
LMP2/7 are still capable of antigen presentation, however 
they appear to process certain antigens inefficiently [11,12]. 
Cells transformed by human adenoviruses of different sero-
type have proven useful in the study of down-regulation of 
class I antigen expression. Adenovirus 12 (Adl2) transformed 
cells exhibit reduced levels of MHC class I mRNA and sur-
face class I molecules and are oncogenic when injected into 
syngeneic animals, whereas cells transformed by Ad5 have 
unaltered or elevated levels of surface class I molecules and 
their mRNAs and are non-oncogenic [13-15]. Recently it has 
been shown that TAP1/2 and LMP2/7 mRNA and protein 
levels are also reduced in Adl2-transformed mouse cells 
[16,17], and in a number of human tumours [18,19]. However, 
the molecular mechanism underlying this down-regulation is 
unknown. Here we show that TAP1 and LMP2 mRNA levels 
are coordinately repressed in Adl2-transformed rat cells. 
Furthermore, we demonstrate that the rat TAP1/LMP2 bidi-
rectional promoter is significantly less active in Adl2-trans-
formed cells compared to Ad5-transformed cells, indicating 
that the reduction in TAP1/LMP2 mRNA levels occurs at 
least in part at the level of transcription. Through comparison 
with previous work on the regulation of MHC class I gene 
expression, we identify a possible common mechanism for the 
down-regulation of MHC-encoded genes involved in antigen 
presentation in Ad 12-transformed cells. 
2. Materials and methods 
2.1. Cell lines 
RFC1 is an Adl2-transformed Hooded Lister rat kidney cell line 
and A12.1 is an Adl2-transformed primary baby rat kidney (BRK) 
cell line (provided by K. Raska). 5A12 is a BRK cell line transformed 
with a recombinant Ad5 virus containing the Adl2 E1A gene [20]. 
A5.2 and Ad5Xho are Ad5-transformed BRK cell lines (provided by 
K. Raska). 3Y1 cells are established Fischer rat fibroblasts. All cells 
were cultured in DMEM supplemented with 10% fetal calf serum, in a 
humidified atmosphere containing 5% CO2 at 37°C. 
2.2. Ribonuclease protection assay 
Total cellular RNA was isolated from Ad-transformed cell lines or 
3Y1 cells using the TRIzol reagent (Gibco/BRL) according to the 
manufacturer's instructions. 
To generate a suitably sized riboprobe for the TAP1 mRNA a 222 
bp Xhol-Pstl restriction fragment from the rat TAP1 cDNA (pro-
vided by G. Butcher) was subcloned into the vector pBluescript SK 
(Stratagene). For the LMP2 riboprobe a 132 bp PCR product was 
amplified from the LMP2 gene (described below) and subcloned into 
the Xbal site of pBluescript SK. Uniformly [a-32P]UTP labeled anti-
sense RNA probes were generated by transcription of linearized plas-
mid templates with T3 or T7 RNA polymerase. 
Purification of full-length RNA probes, hybridisation to cellular 
RNA, and RNase digestion were performed using the RPAII kit 
(Ambion Biotechnology) according to the manufacturer's protocols. 
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Briefly, 15 μg of total RNA was coprecipitated with 1 X 105 cpm of 
antisense probe (TAP1 or LMP2) and resuspended in hybridisation 
buffer. After incubation at 45°C for 18 h, the solution was digested 
with RNase A (2.5 U/ml) and RNase Tl (100 U/ml) at 37°C for 30 
min. Protected fragments were resolved on 6% polyacrylamide/8 M 
urea gels and visualised by autoradiography. 
Protection assays using a 250 bp mouse β-actin antisense probe 
(Ambion Biotechnology) were also performed to control for RNA 
quality and concentration. Size markers were generated by end-label-
ing pUC118 SauiM restriction fragments with the Klenow fragment 
of E. coli DNA polymerase and [ot-32P]dGTP. 
2.3. PCR amplification of rat TAP1 and LMP2 gene sequences 
Genomic DNA was isolated from Wistar rat liver by lysis in 10 mM 
Tris-HCl pH 8.0, 0.1 M EDTA pH 8.0, 0.5% SDS, followed by diges-
tion with RNase A (20 μg/ml) and proteinase K (100 μg/ml), phenol/ 
chloroform extraction and ethanol precipitation. PCR was performed 
using 250 ng of genomic DNA in a volume of 100 μΐ containing 20 
mM Tris-HCl pH 8.75, 10 mM KC1, 10 mM (NH4)2S04, 2 mM 
MgS04, 0.1% Triton X-100, 0.1 mg/ml BSA, 0.2 mM each dNTP, 
0.5 μΜ each primer, and 2.5 U cloned Pfu DNA polymerase (Stra-
tagene). All primers used were designed with Xba\ sites at the 5' end 
to facilitate subcloning of PCR products (not shown). 
Primer pair 5'-GGAACCATGGGAGGGATG and 5'-GTGGT-
GGAACGCCGGCA were used to amplify a 132 bp product from 
exon 5 of the rat LMP2 gene. The PCR cycling conditions were 
denaturation for 5 min at 95°C followed by 30 cycles of 95°C (1 
min), 58°C (30 s), and 72°C (30 s). 
Amplification of the rat TAP1/LMP2 intergenic region was per-
formed using primer pairs Tl (5'-GGCCGCAGCAGCAGCCAGT 
and LI: 5'-AGCCGGCGGTAGGTGCTCC) and T2 (5'-GCTGTC-
CAGAGTCCGGTC and L2: 5'-CCTAGCAGTGCGGAGATC). Tl 
and T2, and LI and L2 are complementary to sequences within the 
first exon of the TAP1 and LMP2 genes respectively (see Fig. 2A). 
PCR cycling conditions were denaturation for 5 min at 95°C followed 
by 30 cycles of 95°C (1 min), 67°C for T1:L1 or 58°C for T2:L2 (45 
s), and 72°C (45 s). The resulting PCR products (681 bp for T1:L1 
and 573 bp for T2:L2) were digested with Xba\ and subcloned into 
pBluescript. DNA sequence was obtained for the entire intergenic 
region from a number of independent clones using the Pharmacia 
T7 polymerase sequencing kit. 
2.4. Transient transfection analysis 
The 573 bp PCR product containing the TAP1/LMP2 intergenic 
region was subcloned in both orientations into the reporter gene vec-
tor pBLCAT3. Cell lines were transfected with the resulting constructs 
using the Lipofectin reagent (Gibco/BRL) and the supplier's recom-
mended conditions. Cells were transfected with a total of 6 μg DNA 
comprising 4 μg test plasmid along with 2 μg CMVpGal control 
plasmid. Cells were harvested 40 h post-transfection and β-galactosid-
ase and CAT activities were assayed using standard methods [21]. 
CAT assays were quantified using a Fuji BAS 1000 phosphorimager. 
The amount of cell extract used in each CAT assay was standardised 
by β-galactosidase activity to account for variation in transfection 
efficiency between cell lines. 
3. Results and discussion 
3.1. TAP1 and LMP2 mRNA levels are coordinately 
down-regulated in Adl2-transformed rat cells 
Expression of MHC-encoded TAP1 and LMP2 genes was 
studied in a series of Ad 12- and Ad5-transformed rat cell lines 
by ribonuclease protection assay. Compared to untransformed 
3Y1 cells steady-state levels of TAP1 and LMP2 transcripts 
were undetectable in the Adl2-transformed cell line A 12.1 and 
10-15-fold lower in the cell line RFC1 (Fig. 1). In contrast, 
Ad5-transformed cells contained 2-6-fold higher levels of 
TAP1 and LMP2 mRNAs compared to 3Y1 cells (Fig. 1). 
No significant differences in the level of β-actin mRNA could 
be detected between cell lines. Similar levels of TAP1 and 
LMP2 transcripts were observed in 3Y1 and untransformed 
BRK cells (results not shown). Rat cells transformed by a 
Fig. 1. Analysis of TAP1 and LMP2 mRNA levels in Ad-trans-
formed cells. Steady-state levels of TAP1 (A), LMP2 (B) and β-actin 
(C) transcripts were determined by ribonuclease protection assay. 
RNA was analysed from Adl2-transformed cells A12.1, RFC1, and 
5A12 (lanes 2-A respectively), from Ad5-transformed cells A5.2, and 
Ad5Xho (lanes 5 and 6 respectively), and from untransformed 3Y1 
cells (lane 7). RNA from yeast (lane 1) was used as a negative con-
trol. Lane P contains undigested probe and lane M DNA size mar-
kers. 
recombinant adeno virus 5 containing the El A region from 
Ad 12 also contained reduced levels of TAP1 and LMP2 
mRNAs compared to 3Y1- and Ad5-transformed cells, indi-
cating that it is the serotypic origin of the El A oncogene 
which determines the level of expression of TAP1 and 
LMP2 genes. It has previously been shown that levels of 
MHC class I mRNAs are greatly reduced in RFC1 and 
5A12 cells compared to Ad5-transformed cells [22]. Therefore, 
expression of multiple genes encoding components of the 
MHC class I antigen presentation pathway is actively re-
pressed in Ad 12-transformed cells. 
3.2. Cloning and sequencing of the rat TAP1ILMP2 intergenic 
region 
Sequencing of human and murine genomic DNA has shown 
that the genes encoding TAP1 and LMP2 are separated by a 
small intergenic region [9,23], and recently it has been shown 
that the human sequence can function as a bidirectional pro-
moter directing the divergent transcription of TAP1 and 
LMP2 transcripts [24]. No genomic sequence data was avail-
able for the rat and therefore, to analyse this promoter in Ad-
transformed rat cells we isolated the equivalent rat sequence 
by PCR amplification of genomic DNA using primers com-
plementary to regions within the 5' ends of previously char-
acterised TAP1 and LMP2 rat cDNA sequences (Fig. 2A). A 
single 681 bp PCR product was obtained and subcloned (re-
sults not shown). Sequence analysis identified the rat TAP1/ 
LMP2 intergenic region to be 564 bp in length, 29 bp shorter 
than the corresponding human sequence (Fig. 2A). The mouse 
intergenic region was originally predicted to be 1007 bp in size 
[23]. However, the presence of an in-frame ATG start codon 
438 bp upstream from that assigned as the start of the TAP1 
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LMP2 
aaccaacaataaatgctccagettacaacatectaacaatacaaagatcTGGTTTCCAAT 3 0 
AGCCGGCGGTAGGTGCTCC(LI) CCTAGCAGTGCGGAGATC(L2) 
CAGCAGCGGCGTGCGGCGAAGGCAACTCTCCGCCTGCGGCCCGCCCCATCGTCGCGCAAG 9 0 
GGGCGTGCCGTTCTACCGAGCATTTGGCGCCCAGAGCTAACTTGAGCAGGGCAGATCTGC 150 
CAGAGACAGGTGACGACAGAGGGTCCCGCCCTAAAGCTGGGGTGGGGCCTGGGATGGGAA 210 
AATTCTCTCAAGCAAGGGGAGAAGACTGGGGAAGGAGAGGAGGATGAGAGTCCTGGAGAA 27 0 












TCTCGGGACTTTCCGCGCACGCCCTCGGACCCGCCCTTCT Rat ** *********** * * ******** * 
TCCTGGGACTTTCCGAGA- -GCCCCGCCCTCGT Human 
Fig. 2. Nucleotide sequence of the rat TAP1/LMP2 intergenic region. A: Nucleotide sequence for the entire rat TAP1/LMP2 intergenic region 
together with partial flanking TAP1 and LMP2 first exon sequences is shown. Predicted TAP1 and LMP2 start codons are underlined and the 
sequence is numbered from the putative LMP2 ATG. Sequence corresponding to that originally obtained from TAP1 [29] and LMP2 [30] 
cDNA clones is shown in lower case and the positions of primers used for PCR are marked. Consensus NF-κΒ and SP1 (GC-box) binding se-
quences are boxed. This sequence has been deposited in the EMBL data base under the accession number X97611. B: Alignment of rat and 
human [24] TAP1/LMP2 intergenic sequences containing consensus NF-κΒ and SP1 binding sequences (underlined). 
coding region, suggests that the mouse intergenic region is 
actually 569 bp in length, just 5 bp longer than the rat se-
quence. Although there is strong conservation between rat 
and mouse intergenic regions (approximately 86% identity), 
overall there is only moderate homology between rodent 
and human sequences (data not shown). However, function-
ally important binding sites for the transcription factors NF-
KB and SP1 have been identified within the human promoter 
[24], and these sites are completely conserved in the rat 
although there is a 9 bp insertion between the two sites in 
the rat relative to the human (Fig. 2B). 
3.3. Expression of the rat TAP1ILMP2 intergenic region in 
Ad-transformed cells 
The rat TAP1/LMP2 intergenic region was subcloned in 
both orientations into pBLCAT3 to generate the reporter 
constructs pTAPlcat and pLMP2cat (Fig. 3A). Transfection 
of Ad5Xho and A5.2 cells with each construct generated sig-
nificant levels of CAT activity compared with the promoter-
less control indicating that the 564 bp intergenic region func-
tions as a bidirectional promoter and is sufficient to mediate 
transcription of both TAP1 and LMP2 genes in Ad5-trans-
formed rat cells (Fig. 3B and results not shown). Levels of 
expression from the TAP1 end of the promoter were higher 
than those from the LMP2 end in both Ad5Xho and A5.2 
cells. Similar results were obtained analysing the activity of 
the human TAP1/LMP2 intergenic region in HeLa cells [24]. 
Transfection of pTAPlcat and pLMP2cat into RFC1 and 
A12.1 cells resulted in 5-8-fold lower levels of CAT activity 
compared to Ad5Xho cells indicating that activity of the 
TAP1/LMP2 bidirectional promoter is significantly reduced 
in Adl2-transformed cells (Fig. 3B). Similar levels of repres-
sion have been observed for a MHC class I heavy chain gene 
promoter (H-2Kb) transfected into Ad 12- and Ad5-trans-
formed cells [25-27], and it has been shown that down-regula-
tion of class I mPvNA levels in Adl2-transformed cells occurs 
predominantly at the level of transcriptional initiation [22]. 
These results imply that reduction in TAP1/LMP2 mRNA 
levels also occurs primarily at the level of transcription. 
3.4. Conclusions 
It has been shown that compared to Ad5-transformed cell 
lines, Adl2-transformed cells contain extremely low levels of 
NF-κΒ capable of binding to DNA, possibly due either to 
144 J.A. Proffitt, G.E. BlairIFEBS Letters 400 (1997) 141-144 
1 ™lr CAT pTAPIcat 
£ I CAT pLMP2cat 
B 
Fig. 3. Activity of the TAP1/LMP2 bidirectional promoter in Ad-
transformed cells. A: Schematic diagram of reporter gene constructs 
obtained by cloning the TAP1/LMP2 intergenic region into 
pBLCAT3 in both orientations. B: Constructs pTAPIcat (T) and 
pLMP2cat (L) were each co-transfected with the control plasmid 
CMVpGal into Ad 12- and Ad5-transformed cell lines. Resulting 
CAT activity (normalised for β-galactosidase activity) is presented 
as percentage conversion of [14C]chloramphenicol to its acetylated 
derivatives. Transfections were performed at least three times with 
more than one batch of each plasmid and representative results are 
shown. 
induction of a nuclear inhibitor of NF-κΒ function or inhibi-
tion of processing of the pl05-NF-KB precursor by the Adl2 
E1A protein [25,26,28]. The difference in MHC class I mRNA 
levels between Ad 12- and Ad5-transformed cells has been at-
tributed to the resulting differential binding of NF-κΒ to an 
enhancer element within the MHC class I promoter. As de-
scribed above, a consensus binding site for NF-κΒ is also 
present within the rat TAP1/LMP2 promoter, and this se-
quence is fully conserved between rat and human (see Fig. 
2B). Mutational analysis of the human TAP1/LMP2 promoter 
has demonstrated that this site is important for expression 
[24], and initial protein binding studies show that the rat se-
quence is capable of binding NF-κΒ family members in vitro 
(results not shown). We suggest that by targeting N F - K B , 
Ad 12 can repress multiple components of the MHC class I 
peptide presenting pathway at the level of transcription, thus 
resulting in greatly reduced expression of class I molecules at 
the cell surface and escape from immune surveillance. 
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